Pregnant women were a high-risk population for influenza infection. The applicability of novel subunit vaccinations has not been thoroughly researched. Prospective, randomized, open-label comparison of subunit and polymeric subunit (Agrippa) and polymeric subunit (Grippol plus) vaccines. The research included 42 mother-infant pairings. Protective antibodies to distinct influenza strains were detected on day 1 after delivery in 53% of instances in pairs of mothers-infants following immune adjuvant polymeric subunit and subunit vaccination administration. After 3 months, mothers had the same level of protective antibodies (AB), but transplacental antibodies reduced among newborns and were found in 13–22% of cases in the Grippol plus group and 31 to 43% of cases in the Agrippa S1 group. In the first days after delivery, AB titer to influenza viruses A/H1N1/pdm09 and A/H3N2/in pairs of mothers-newborns were the same in both groups, while AB levels to B strain were lower among infants regardless of vaccination. At 3 months of age, there was no difference in AB titers between the two groups, however, their levels were twice lower than the original data. The usage of an immune adjuvant polymeric subunit, as well as subunit vaccinations in pregnant women, resulted in the formation of protective AB in pairs of mothers-infants.